Meth-A sarcoma cells were stable transfected to overexpress (sense construct) or underexpress (antisense construct) tissue factor. In vitro, there was no difference in plating efficiency or growth between these cell lines.
Introduction
Tissue factor, the principle initiator of coagulation in vivo ( 1, 2) , has been studied extensively in terms of its contribution to hemostasis and thrombosis (3) . Consistent with a protective role in the hemostatic response, tissue factor is present only in subendothelial layers of the vessel wall, the interstitium, and is distributed throughout the subcutaneous tissue (4) .
Although constitutive expression of tissue factor is a characteristic feature of multiple neoplastic cells, the role of this integral membrane protein in the biology of tumors is not clear. Reports from both clinical studies and experimental models describing a correlation between blockade of activation of coagulation and reduced tumor growth (5-7) suggest a potential contribution of the procoagulant mechanism, initiated by tissue factor, beyond hemostasis. Growth of solid tumors depends on their mitotic rate, their ability to evade the host response and the effectiveness with which they elicit neoangiogenesis.
The identification of tissue factor as a growth-related immediate early gene (8-1O), whose transcription is initiated coordinately with the induction of cell proliferation, suggests a possible role for tissue factor beyond the coagulation mechanism. Here we report that tissue factor regulates the balance of angiogenic and anti-angiogenic properties of tumor cells. By controlling tissue factor expression in Meth-A sarcoma tumor cells using molecular techniques, its role in these facets of tumor biology has been assessed. Expression of tissue factor is essential for the growth of solid tumors, since tissue factor controls the balance of angiogenic and antiangiogenic tumor cell activities.
Methods
Production of transfected tumor cells. Stable transfectants of Methylcholantrene-A-induced murine fibrosarcomas (Meth-A sarcoma) cells were prepared with tissue factor cDNA (7) (generously provided by D. Nathans, Baltimore, MD) cloned into pXT1 expression vector (Stratagene, La Jolla, CA), which contains the LTRs, a portion of the gag gene from Moloney Murine Leukemia Virus and the Herpes Simplex Thymidine Kinase promotor ( Fig. 1) (11) . The tissue factor insert spanned the whole translated region of the tissue factor gene, including sense, truncated sense (the latter producing an inactive tissue factor gene product due to deletion of the factor VII binding region and due to cloning it in the wrong reading frame), and antisense constructs, cloned into pXTI. pXTI contains a selectable neomycin gene under control of the LTR, conferring G418 resistance ( 12). Transfection with each of these constructs or vector alone was performed using Lipofectin (GIBCO BRL, Gaithersburg, MD). 5 Figure 1 . Expression system of mouse tissue factor. The full length of mouse tissue factor (mTF) cDNA was inserted into BglIl site under TK promoter as both direction. Sense construct is 5'-3' and antisense construct is 3'-5'. Truncated sense is partial of mTF gene spanned from 407 bp to the end under TK promoter in 5 '-3' direction. V, vector; TS, truncated sense; S. sense; AS, antisense; LTR, Moloney murine leukemia virus LTRs; Neo, neomycin-resistance gene; TK, herpes simplex thymidine kinase promoter; TF, mouse tissue factor gene.
The cells were cultured at 370C and 5% CO2 for 24 h. An additional 3 ml of cell culture medium containing 20% FCS and antibiotics was added on the second day. On the third day cells were split and medium containing 10% FCS and 0.8 mg/ml of G418 (GIBCO BRL) was added (13) . The selection medium was changed every 3 d. Colonies of stable transfected cells were seen after 2 wk. All colonies (70-100 colonies in each transfectant) were used together for generation of a single cell line.
Determination of tissue factor expression. Western blots were performed as previously described (14) . Tumor cells were scraped and washed three times with 0.9% NaCl, then lysed in 1 x SDS loading buffer (50 mM Tris, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, 10% glycerol). The tumor cell lysate was sheared with a 27-gauge needle and heated at 100°C for 10 min. After being separated in SDS-PAGE, the proteins were electro-transfered onto Hybon-C extra membrane (Amersham International, Buckinghamshire, England). After the filter was dried on air for 20 min, it was blocked with 5% nonfat milk in PBS, and incubated with anti-mouse tissue factor (described below) for 60 min. The membrane was washed three times with PBS before incubation with second antibody (goat antirabbit IgG, conjugated with alkaline phosphatase). The color was developed by BCIP (5-Bromo-4-chloro-3-indolyl-phosphate, X-phosphate) and NBT (4-Nitro blue tetrazolium chloride) (Boehringer Mannheim Biochemica, Mannheim, Germany). The polyclonal antibody against recombinant mouse tissue factor was raised in rabbits. Its specificity has been demonstrated by reacting positive with cells transfected with tissue factor sense and negatively in cells transfected with tissue factor antisense cDNA. It also reacted negatively with mouse endothelial cells in vivo, while it reacted positive with wild-type tumor cells in vivo (data not shown). Furthermore the band recognized in wild-type tumor :ells was the same as in tissue factor transfected cells (see Fig. 2 A) .
rissue factor activity was determined by a one stage clotting assay. rumor cells were scraped, washed three times with BBS, pH 7.4 (15).
For one stage clotting assay 105 tumor cells were given to 100 p1 BBS md 100 41 mouse citrated plasma. After mixing, 100 ILI of 100 mM ZaCl2 was added. The time until formation of definite fibrin strands at 370C was noted. A standard curve for determination of relative tissue actor units was performed with different numbers of wild-type tumor *ells. The clotting time obtained with 105 wild-type tumor cells was lefined as 100 arbitrary units (see Fig. 2 B) .
Proliferation assay. Anticoagulation of mice with warfarin. Mice were maintained on drinking water supplemented with the warfarin (Sigma Chemical Co.) derivative 3-(a-acetonylbenzyl)-4-hydroxycoumarin (8 mg/l) for 3 d before planting of tumor cells. The mice were given normal water after Meth-A cells were injected. Before carrying out an experiment with the anticoagulated animals, a factor X assay on the mouse plasma was performed. Only animals with factor X levels of < 10% were used (18) .
Endothelial cell studies. Human umbilical vein endothelial cells (HUVEC) were cultured as previously described (19) . To obtain conditioned medium, tumor cell were cultured in serum free, or containing 10% FCS, RPMI 1640 without G418 over 12 h. To study the effect of tumor cell conditioned medium on endothelial cell proliferation, HUVEC were seeded at the density shown in Fig. 7 , A and B. 1 ml of tumor cell conditioned medium was added to 1 ml of RPMI 1640, containing 20% FCS, but no growth factors. When the effect of hirudin was tested, 0.5 U/ml of hirudin (Sigma Chemical Co.) were added to the tumor cell medium. The endothelial cells were counted by two investigators at the indicated time points.
Nuclear run on transcription assay. Nuclear run on transcription assay was performed essentially according to the method by Greenberg and Ziff (20) , as modified by Almendral et al. (9) . The cDNA of mouse vascular endothelial cell growth factor/vascular permeability factor (VEGF/VPF)' was a generous gift of Dr. W. Risau (Max Planck Institute, Munich, Germany) the cDNA of mouse thrombospondin-2 (TSP2) was a generous gift of Dr. Bornstein (University of Washington, Seattle, WA). Nuclear run ons were performed with a 583-bp BamHIEcoRI insert of mouse VEGF gene and exon 4-7 of mouse TSP2 gene cells transfected with the full-length tissue factor sense construct expressed more tissue factor antigen and procoagulant activity than cells transfected with vector alone, based on Western blotting, one stage clotting assay (a measure of tissue factor activity) (Fig. 2, A and B) and immunohistochemistry of cultured cells (Fig. 2 C) (Fig. 2 C) . Proliferation of Meth-A cell lines expressing different amounts of tissue factor was studied in culture by determining changes in cell number (Fig. 3 A) . Plating efficiency and growth of all four cell lines was identical, as was the expression of basic fibroblast growth factor, the latter based on Western blots (data not shown). This suggested that tissue factor expression is not an important factor for proliferation or survival of Meth-A cells in culture. Since survival and growth of solid tumors in vivo is not only dependent on seeding efficiency and proliferation as tested in vitro, but also on vascularization and interaction with the immune system, we studied growth of the tumor mutants in vivo.
Cells from the four Meth-A transfectants were injected intracutaneously into C3H mice to examine tumor growth. Each mouse was inoculated with all four of the tumor lines, each in a different location. Tumor growth was quantitated based on tumor size/weight (Fig. 3, B and C) . In contrast to the comparable proliferation of the Meth-A cell lines in vitro, the antisense cell line grew slowly in vivo, compared with cells transfected with vector alone or the truncated sense construct. The difference observed between sense and antisense transfectants (Fig.  3 B) was statistically significant after day 4 (P < 0.01). The difference between sense and vector was statistically significant after day 8 (P < 0.05). The growth of the antisense transfectants was significantly retarded already at day 4 (P < 0.05).
Consistent with these results the weight of sense tumors was greater than vector (P < 0.01) or truncated sense (P < 0.01), antisense transfectants weighted the least (P < 0.001) (Fig. 3  C) . Immunostaining for tissue factor demonstrated expression in the tumor cell population which was constant and comparable with that observed in tissue culture (Fig. 4) . Tumor derived from antisense transfectants expressed much lower levels of tissue factor antigen, compared with vector or truncated sense transfectants. Tissue factor antigen was most prominent in tumor grown from sense transfectants. To exclude that the increased growth rate of sense transfectants is due to activation of coagulation, we repeated above experiments in mice anticoagulated with Warfarin, sense transfectants grew larger, and antisense transfectants showed a retarded growth (Fig. 5, A and B).
Mechanism of enhanced tumor growth of transfected cell lines expressing increased levels of tissue factor. These data indicated that expression of tissue factor by tumor cells facilitated tumor development in vivo. Since tissue factor did not directly influence tumor cell proliferation in vitro, two alternative hypotheses were considered. Tissue factor-mediated activation of coagulation, which has been speculated to result in a protective fibrin cocoon about the neoplasm, could prevent tumor destruction by host immunologic mechanisms (6) . To assess this possibility, the experiments described above were repeated in nude mice with similar results (Fig. 5 C) . In addition, the nonimmunogenic B16 melanoma line transfected with the antisense tissue factor construct demonstrated coordinate blockade of tissue factor expression and reduced growth in vivo (not shown). Furthermore, spontaneous rejection of each of the four Meth-A derived cell lines was observed in C3H mice at about 16 d, consistent with comparable immunogenicity. These data suggested that mechanisms other than tumor-immune effector cell interactions were important in tissue factor-regulated growth of tumors.
An important factor in the successful establishment of a solid tumor nidus is the induction of neoangiogenesis, providing the tumor with nutrients critical for growth of the tumor cells (24) . When vascularization of tumors derived from Meth-A cells transfected with each of the tissue factor constructs was compared, a greater density of vessels was evident in the tumors which expressed increased levels of tissue factor (sense construct) (Fig. 6 A) . Tumors expressing levels of tissue factor comparable to that observed in wild type Meth-A cells (i.e., those Meth-A cells transfected with vector alone or truncated tissue factor sense construct) showed a similar degree of vascularization, but less than in the sense construct. The lowest degree of vascularity was consistently seen in tumors expressing no tissue factor (antisense construct).
Estimation of tumor blood flow, based on perfusion with 10-,qm latex microspheres, which become trapped in the microvessels, supported the results of the morphologic studies (Fig. 6 B) . The number of microspheres per gram tumor tissue was the greatest in the tumors expressing high levels of tissue factor (sense construct), lower in the tumors expressing tissue factor levels comparable with wild type (vector or truncated sense construct, P < 0.005), and the lowest in the tumors of the antisense construct (P < 0.001). Therefore tissue factor facilitates tumor growth in vivo by enhancing angiogenesis. Effect of tissue factor on release of mitogenic activity for endothelial cells. This led us to examine if there was a relationship of tissue factor expression by tumor cells and the release of growth factor(s) for endothelial cells. When the conditioned media of the four transfected cell lines was tested, a difference in their mitogenic activity for cultured endothelial cells was noted (Fig. 7 A) . Proliferation of human umbilical vein endothelial cells in medium not supplemented with growth factor was stimulated the most by supernatant from sense transfected Meth (Fig. 7 B) , consistent with the inability of coumadin to reverse the growth induction by tissue factor in vivo. Therefore the effect of tissue factor on tumor cell mediated angiogenesis is independent of thrombin formation.
Since angiogenesis results from a balance of angiogenic and antiangiogenic activities, we tested the stable transfected Meth-B Figure 7 . (Fig. 8 A) . In contrast antisense tissue factor transfectants had a decreased rate of VEGF/VPF transcription and a higher rate of thrombospondin transcription. These data suggest that tissue factor expression is closely correlated with induction of a tumor-derived angiogenic factor, VPF/VEGF, which has been speculated to have an important role in tumor growth (24) (25) (26) (27) (28) (29) . This has also been confirmed by Northern analysis (Fig. 8 B) of Meth-A sarcoma cells. Thus tissue factor expression influences expression the angiogenic VEGF/VPF and the antiangiogenic thrombospondin.
Discussion
These data suggest the possible significance of tissue factor as an immediate early gene (8, 9) : coordinate expression of tissue factor with induction of cell proliferation allows the tumor cells to more effectively elicit a neoangiogenic response critical for their growth and survival in vivo. Tissue factor, which shares distant homologies with the gene superfamily of receptors for hematopoietic growth factors and cytokines, can also be considered a "competence gene," an alternative name assigned to the "immediate early genes" (10, (30) (31) (32) (33) (34) , which facilitates endothelial cell ingrowth and capillary formation by "progression factors," the angiogenesis factors. However it remains unclear if the link of tissue factor expression to angiogenesis is present in all cells or only in Meth-A sarcoma and B-16 melanoma (data not shown) studied here. Tumors are frequently surrounded by fibrin, suggesting that tissue factor overexpression might be due to tissue factor-factor Vila-dependent thrombin formation. To exclude this possibility, mice were anticoagulated with coumadin. Anticoagulation of mice with coumadin did not affect growth induction observed in tumors overexpressing tissue factor. Furthermore, the difference in the mitogenic effects of tissue factor sense, truncated sense, vector, and antisense transfectants on the growth of endothelial cells was not decreased in serum free medium or by the addition of hirudin. Therefore the effect of tissue factor on tumor growth, vascularization, and elaboration of angiogenic stimuli appears to be independent of coagulation. This raises the question of the mechanism by which tissue factor elicits an angiogenic response in the tumors tested.
In this study we show that transcription of an important mediator of angiogenesis, VPF/VEGF is induced by stable transfection of tumor cells with tissue factor cDNA in the sense orientation, but suppressed when cells were transfected with tissue factor cDNA in the antisense orientation. The mechanism linking expression of tissue factor to thrombospondin and VPF/ VEGF expression remains to be elucidated. One possible route by which tissue factor might influence expression of other genes is through phosphorylation of its cytoplasmic tail. However, to date, neither the signals required for inducing phosphorylation nor the intracellular events dependent on phosphorylation of tissue factor are known. Future studies with tissue factor mutants lacking the phosphor acceptor side will be necessary to clarify if phosphorylation of tissue factor results in alteration of gene expression.
These studies emphasize the integral role that tissue factor has in tumor biology, in addition to its well known function as the central procoagulant cofactor which initiates activation of the coagulation pathway. 
